Immune Privilege and Eye-Derived T-Regulatory Cells.

Immune Privilege and Eye-Derived T-Regulatory Cells.
复制标题

DOI:
10.1155/2018/1679197
复制
发表时间:
2018
影响因子:
4.1
通讯作者:
Sugita S
Sugita S
中科院分区:
医学3区
文献类型:
--
作者:
Keino H;Horie S;Sugita S

文献摘要

参考文献

被引文献

相似文献

眼睛的某些细胞成分,如神经视网膜,在破坏性炎症后无法再生和复制。眼免疫豁免为眼睛提供针对眼内炎症的免疫保护,以最大限度地降低视力完整性的风险。眼和免疫系统通过调节先天性和适应性免疫应答(包括免疫忽略、对眼源性抗原的外周耐受和眼内免疫抑制微环境)来使用策略来维持眼免疫赦免。本文综述了调节性T细胞(Treg)和眼内驻留细胞(包括角膜内皮细胞、眼色素上皮细胞和眼房水)参与眼免疫赦免的分子机制。此外,我们检测了由表达转化生长因子β(TGF-β)、细胞毒性T淋巴细胞相关抗原-2 α(CTLA-2α)和视黄酸的RPE细胞产生的TCR 4对自身免疫性葡萄膜视网膜炎的治疗潜力,并评估了使用人RPE诱导的TCR 4用于炎性眼病临床应用的新策略。我们相信,更好地了解与Teptide相关的眼部免疫豁免可能为眼部自身免疫的治疗干预提供新的方法。
Certain cellular components of the eye, such as neural retina, are unable to regenerate and replicate after destructive inflammation. Ocular immune privilege provides the eye with immune protection against intraocular inflammation in order to minimize the risk to vision integrity. The eye and immune system use strategies to maintain the ocular immune privilege by regulating the innate and adaptive immune response, which includes immunological ignorance, peripheral tolerance to eye-derived antigens, and intraocular immunosuppressive microenvironment. In this review, we summarize current knowledge regarding the molecular mechanism responsible for the development and maintenance of ocular immune privilege via regulatory T cells (Tregs), which are generated by the anterior chamber-associated immune deviation (ACAID), and ocular resident cells including corneal endothelial (CE) cells, ocular pigment epithelial (PE) cells, and aqueous humor. Furthermore, we examined the therapeutic potential of Tregs generated by RPE cells that express transforming growth factor beta (TGF-β), cytotoxic T lymphocyte-associated antigen-2 alpha (CTLA-2α), and retinoic acid for autoimmune uveoretinitis and evaluated a new strategy using human RPE-induced Tregs for clinical application in inflammatory ocular disease. We believe that a better understanding of the ocular immune privilege associated with Tregs might offer a new approach with regard to therapeutic interventions for ocular autoimmunity.
DOI: 10.4049/jimmunol.166.1.26
发表时间: 2001-01-01
影响因子: 4.4
作者:
D'Orazio, TJ;Mayhew, E;Niederkorn, JY
通讯作者: Niederkorn, JY
DOI: 10.1126/science.270.5239.1189
发表时间: 1995-11-17
期刊: SCIENCE
影响因子: 56.9
作者:
GRIFFITH, TS;BRUNNER, T;FERGUSON, TA
通讯作者: FERGUSON, TA
DOI: 10.1016/s0002-9394(02)02055-x
发表时间: 2003-04-01
影响因子: 4.2
作者:
Hargrave, S;Chu, YL;Niederkorn, J
通讯作者: Niederkorn, J
DOI: 10.4049/jimmunol.182.1.148
发表时间: 2009-01-01
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者:
Chauhan SK;Saban DR;Lee HK;Dana R
通讯作者: Dana R
DOI: 10.1038/83713
发表时间: 2001-01-01
期刊: NATURE GENETICS
影响因子: 30.8
作者:
Bennett, CL;Christie, J;Ochs, HD
通讯作者: Ochs, HD